Page 20 - Serum Institute Of India

Health Minister inaugurates India's first pneumococcal conjugate vaccine

Union Health Minister Dr Harsh Vardhan On Monday inaugurated India's first pneumococcal conjugate vaccine "Pneumosil", which has been developed by the Serum Institute of India

Nod for Covid vaccine in the next few days: Serum Institute's Poonawalla

SII has stockpiled 40-50 mn doses and is adding more every week. Most of these will come to India, as exporting would require fulfilling WHO's pre-qualification procedures

Vardhan launches indigenously developed pneumococcal vaccine 'Pneumosil'

Pneumosil was found to be safe and effective in the prevention of pneumonia and based on which Pneumosil has been licensed by the Drugs Controller General of India in July 2020

India's first fully indigenous pneumococcal vaccine launched

Serum Institute of India announced the launch of India's first indigenously developed pneumococcal vaccine -- Pneumosil

We are researching two candidates for Covid vaccines: Serum Institute CEO

In an e-mail interview with Sohini Das, Adar Poonawalla, chief executive officer, Serum Institute of India, says the firm is not raising additional capital through private equity

Faltering health infra gets a shot in the arm as vaccine roll-out nears

As an extraordinary year is drawing to a close, a seven-part series looks at the key areas that are on the cusp of dramatic changes

Bharat Biotech halfway through in one of country's largest phase-3 trials

Pfizer yet to submit data to regulator while Serum Institute has provided all additional information for emergency use authorisation

India likely to approve AstraZeneca vaccine by next week: Sources

This could be the first country to give the regulatory green light for the British drugmaker's vaccine as the British medicine regulator continues to examine data from the trials

India requires Rs 80,000 cr for vaccine distribution next year: Serum

Serum Institute of India said that the country would require a massive funding of Rs 80,000 crore for distribution of the Covid vaccine for the next one year

Global partnership COVAX secures 2 billion coronavirus vaccine doses

Global vaccine partnership COVAX has lined up almost two billion doses of existing and candidate Covid-19 vaccines for use worldwide

Serum Institute to seek nod for two full-dose regimen of Covishield

Suresh Jadhav, executive director of the Pune-based firm, said on Friday Serum was seeking approval from the Drug Controller General of India (DCGI) for the two-full dose regimen

India seeks to mend Bangladesh ties with coronavirus vaccine diplomacy

The new law fast-tracks Indian citizenship for non-Muslims from three neighboring nations including Bangladesh

Serum likely to submit final Covid-19 vaccine trial data in 10 days

If the data is found satisfactory, an approval for Covishield, Oxford-AstraZeneca's vaccine candidate, can come in by the first week of January

Codagenix, Serum to start UK trials of nasal Covid vaccine in January

The companies said 48 volunteers will be enrolled at three dose levels and expect to begin dosing the trial participants in the first week of January

Chennai Covishield volunteer to move court against Serum Institute

Serum Institute of India said the volunteer was "falsely laying the blame for his medical problems on the vaccine trial"

Serum Institute vax volunteer not ready to withdraw legal notice

A Chennai-based volunteer had developed severe neurological complications after first dose of vaccination of Covishield which is under development at Serum Institute

World is watching India for 'safe' Covid vaccine, but are we ready?

Review panel asks vaccine makers to submit more data to get authorisation

Experts ask Bharat Biotech for phase 3 data, Serum's UK approval status

Provide more safety data on Covid-19 vaccine: SEC to Serum, Bharat Biotech

The application submitted by the Pfizer was not discussed at the SEC meeting as the company has requested for more time for giving its presentation

Trust DCGI to ask for enough data before vaccine approval: Gagandeep Kang

Having achieved the first goal of seeing whether the vaccines work, we can be more ambitious and design studies to assess whether and how much they reduce transmission, says Kang